electroCore,

electroCore, Net Debt / EBITDA

The Net Debt to EBITDA of electroCore, (ECOR) as of Oct 20, 2026 is 0.16. In the previous year, Net Debt to EBITDA was 0.64 — a change of -74.92% (lower).

Net Debt / EBITDA

0.16

YoY

-74.92%

Last updated:

Net Debt to EBITDA of electroCore, is 2025 0.16 . Net Debt to EBITDA of electroCore, was 2024 0.64 . It decreases by -74.92% lower compared to the previous year.

The electroCore, Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2016
-0.46 USD
Jan 1, 2019
0.48 USD
Jan 1, 2020
0.80 USD
Jan 1, 2021
1.69 USD
Jan 1, 2022
0.74 USD
Jan 1, 2023
0.52 USD
Jan 1, 2024
0.64 USD
Jan 1, 2025
0.16 USD
The electroCore, Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.16-74.92%
0.64+24.80%
0.52-30.61%
0.74-56.06%
1.69+111.59%
0.80+67.28%
0.48-203.80%
-0.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Net Debt to EBITDA of electroCore, is 0.16 in 2025.

Net Debt to EBITDA of electroCore, changed from 0.64 to 0.16, representing a -74.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA electroCore, since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's electroCore, with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — electroCore,

All Key Metrics — electroCore,